Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Telephus Biosciences LLC is active in the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 1 pending office action. This action is situated in 1 distinct art unit, reflecting a focused approach to patenting within the biological and pharmaceutical sciences.
The prosecution involves a distinct examiner, HADDAD, MAHER M. This examiner is the busiest for the portfolio, holding a busiest examiner pending action. Since the pending office action is the only one currently active, the practitioner's focus is entirely on the examiner. The distinct art unit and examiner structure means there is no variation in the examination process across the portfolio at this time. This busiest examiner pending action represents the total current workload, simplifying the management of the pending office action for the legal team.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264895 | ANTIBODIES THAT BIND GLUCOSAMINIDASE AND USES THEREOF | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264895 | ANTIBODIES THAT BIND GLUCOSAMINIDASE AND USES THEREOF | HADDAD, MAHER M | 1641 | §112 | Non-Final OA | — | Pending | Aug 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTelephus Biosciences LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maher M Haddad has the most, with 1 of Telephus Biosciences LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
